Town Hall Session - Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

	Joyce L. Ross, MSN, ANP, CRNP, CLS, FNLA President, National Lipid Association Program Chair University of Pennsylvania Health System- Retired Philadelphia, PA		Dave L. Dixon, PharmD, BCPS, CDE, AACC, FNLA Planning Committee Member Associate Professor, Ambulatory Care Vice-Chair of Clinical Services Department of Pharmacotherapy and Outcomes Science Virginia Commonwealth University School of Pharmacy Richmond, VA
	Joseph J. Saseen, PharmD, CLS, FNLA Professor Clinical Pharmacy & Family Medicine University of Colorado Denver Anschutz Medical Campus Aurora, CO		Dean A. Bramlet, MD, FNLA Assistant Consulting Professor of Medicine Duke University Medical Director, Cardiovascular Diagnostic Center The Heart & Lipid Institute of Florida St. Petersburg, FL Diplomate, American Board of Clinical Lipidology
	Daniel J. Rader, MD, FNLA Seymour Gray Professor of Molecular Medicine Chair, Department of Genetics Chief, Division of Translational  Medicine and Human Genetics Department of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, PA Diplomate, American Board of Clinical Lipidology

This Town Hall Session was an exciting kick-off to the NLA’s Annual Scientific Sessions. Co-chaired by NLA President Joyce Ross, and Dr. Dixon, the faculty reviewed the history of lipid lowering therapy and projected what is still to come. To start this session, Dr. Saseen reviewed the “PAST” clinical experiences with lipid-lowering drug therapy. He covered the history of statin therapy by focusing on landmark statin trials that have influenced lipid management. In contrast, select evidence using nonstatin therapy was included. Dr. Bramlet covered the “PRESENT” with regard to lipid-lowering drug therapy. He reviewed newly released outcomes data with PCSK9 inhibitors and identify how they are changing the landscape of lipid management. The role of omega-3 fatty acids was included and a discussion on how to use these medications to treat patient populations without clear outcomes data in patients with triglyceride values < 500 mg/dL. This session concluded with Dr. Radar identifying “FUTURE” targets of emerging therapy. There are exciting potential medications that modify Lp(a), ApoC3 and triglyceride-rich lipoproteins.

Stay tuned for more details on our CME/CE digital enduring activity launching on Healio.com and LipidCE.com.
Enduring webcast in production with